PROSTATE WARRIORS - The latest news about prostate cancer
  • Home
  • Cancer 1O1
  • News
  • TRIALS TABLE
  • Navigator
  • Newsletters
  • tE2 Initiative
  • Contact
  • Search
  • Menu Menu
  • X

EcDNA and Prostate Cancer: A New Frontier in Understanding Resistance

January 29, 2025/in Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-29 14:18:522025-01-29 14:18:52EcDNA and Prostate Cancer: A New Frontier in Understanding Resistance

Hydrogel Breakthrough May Improve Cancer Vaccines

January 29, 2025/in Immunotherapy, Not PCa related, Preclinical Research/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-29 13:20:362025-01-29 13:20:36Hydrogel Breakthrough May Improve Cancer Vaccines

CaRe Trial Expands to Include Veterans

January 29, 2025/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-29 13:13:012025-01-29 13:13:01CaRe Trial Expands to Include Veterans

New Study Targets Tumor Cell Clusters to Combat Metastasis

January 25, 2025/in Not PCa related/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-25 07:25:012025-01-25 08:57:59New Study Targets Tumor Cell Clusters to Combat Metastasis

Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC

January 24, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-24 16:31:032025-01-24 16:31:03Phase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC

Phase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers

January 24, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-24 15:55:072025-01-24 15:55:07Phase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers

AAA817 (225Ac-PSMA-617) Phase2/3 Trial Will Start Recruiting Soon

January 24, 2025/in Clinical Trial, Metastatic, Phase 2/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-24 15:39:312025-01-24 20:25:41AAA817 (225Ac-PSMA-617) Phase2/3 Trial Will Start Recruiting Soon

IPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4

January 24, 2025/in Clinical Trial, Metastatic, Phase 1/by Max
Read more
https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png 0 0 Max https://prostatewarriors.com/wp-content/uploads/2024/10/prostate-warriors-logo-300x138.png Max2025-01-24 15:20:402025-01-24 15:20:40IPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
Page 65 of 81«‹6364656667›»

Menu

  • Home
  • Cancer 1O1
  • News
  • TRIALS TABLE
  • Navigator
  • Newsletters
  • tE2 Initiative
  • Contact

Categories

Archives

  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • September 2023

Project Navigator


Let's try to finance it!

A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.

Tags

177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy

Latest Posts

  • Newsletter 24/2026 June 14, 2026
  • Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
  • UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
  • BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
© Copyright 2024 - 2025 PROSTATE WARRIORS - The latest news about prostate cancer - Supporters' Hall
  • X
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only